Trade Mark Journal No.2025/035 29 August 2025

UK00004250775 18 August 2025 (5)

VIKHEYLO

International priority date claimed: 20 February 2025 (United States of America) (99049558)

Class 5: Pharmaceutical preparations for the treatment of hereditary angioedema; Pharmaceutical and biological preparations; Pharmaceutical and biological preparations for treating and managing hereditary angioedema (HAE) and complications caused by hereditary angioedema (HAE); Pharmaceutical and biological preparations, namely, gene editing preparations for use with protein disorders and genetic diseases; Intravenous injectable gene therapy preparations for treating and managing swelling attacks; Therapeutic agents in the nature of CRISPR/Cas9 protein with guide RNAs targeting the KLKB1 gene to reduce production of plasma prekallikrein and control bradykinin generation.

Intellia Therapeutics, Inc.

Representative: D Young & Co LLP